
CD47
Targeting multiple solid tumors and NHL, with clinical trials are being conducted across multiple hospitals in Taiwan, the United States, and Mainland China, targeting various solid tumors.
Preclinical studies showed limited red blood cell phagocytosis, as well as strong antitumor activity and greater tumor growth inhibition than tested CD47-targeting comparators in selected animal models. These findings also support HCB101’s potential to link innate and adaptive antitumor immunity and its further development as monotherapy or in combination.
Monotherapy use.
No dose-limiting toxicities (DLTs) were observed at the evaluated dose levels, based on available Phase 1a clinical data.
Partial responses (PRs) were observed in patients treated with HCB101 during the Phase 1a study.
Combination therapy with standard of care (SOC).
Target indications include head and neck cancer, triple-negative breast cancer, gastric cancer, and colorectal cancer.
HCB101 is an investigational SIRPα-based immuno-oncology biologic developed using HanchorBio’s proprietary FBDB™ technology platform. It is designed to block the CD47–SIRPα innate immune checkpoint and enhance macrophage-mediated phagocytosis of tumor cells while minimizing interactions with red blood cells. HCB101 is being evaluated in clinical trials for its safety, tolerability, and preliminary antitumor activity in patients with solid tumors. Preclinical findings and emerging clinical observations support its further development as a macrophage-directed immunotherapy and a potential backbone for combination therapies.
CD47, PD-L1, and TGF-β (transforming growth factor beta).
Targeting multiple solid tumors and non-Hodgkin’s lymphoma (NHL).
Monotherapy use.
IND approvals obtained from the U.S. FDA, Taiwan TFDA, and China NMPA.
First patient enrolled and dosed.
HCB301 is an advanced, investigational tri-functional Fc-fusion protein. It integrates an engineered SIRPα domain, an anti-PD-L1 VHH, and an engineered TGF-β receptor to simultaneously target CD47, PD-L1, and TGF-β. HCB301 is designed to activate macrophages and T cells by enhancing macrophage phagocytosis and restoring T-cell activity, while reducing immunosuppression within the tumor microenvironment (TME). By coordinating innate and adaptive immune responses, HCB301 is being investigated for its safety, tolerability, and preliminary antitumor activity in patients with advanced solid tumors.
CD47, PD-L1 and TIGIT ligands
HCB303 has received IND clearance from the U.S. FDA and IND approval from Taiwan’s TFDA. Preparations for its Phase 1 first-in-human clinical trial are underway.
HCB303 is an innovative, investigational humanized trispecific fusion protein developed using HanchorBio’s proprietary FBDB™ technology platform. Using the IgG antibody Fc region as a backbone, it incorporates protein domains targeting three distinct immune pathways—SIRPα/CD47, PD-L1/PD-1, and TIGIT/PVR—providing multiple biological activities and enabling the simultaneous inhibition of multiple immunosuppressive signaling pathways.
By integrating these mechanisms within a single molecule, HCB303 aims to coordinate macrophage, T-cell, and natural killer (NK)-cell antitumor responses through the combined modulation of innate and adaptive immunity. It is being developed as a potential treatment for solid tumors. Following HCB301, HCB303 is the second trispecific candidate developed through the FBDB™ platform to receive authorization for human clinical trials. It has received U.S. FDA IND clearance and Taiwan TFDA IND approval, supporting advancement into Phase 1 first-in-human clinical evaluation.
CD47 and CD20
Focused on B-cell malignancies and autoimmune diseases.
Preclinical development, with planned IND submissions for oncology and autoimmune indications.
HCB206 is an investigational dual-target fusion protein biologic developed using HanchorBio’s proprietary FBDB™ platform. It targets CD20 and engages the CD47–SIRPα pathway. It is designed to promote immune-mediated clearance of pathogenic B cells and is being developed for autoimmune diseases. HCB206 also has potential applications in B-cell malignancies. Its development marks HanchorBio’s strategic expansion of its proprietary technology platform beyond oncology immunotherapy into the rapidly growing autoimmune disease market.
As autoimmune diseases remain incurable, patients require lifelong treatment, creating substantial and continuously expanding unmet medical needs.
HCB206 is currently in late-stage preclinical development, including IND-enabling studies. In preclinical studies, it has demonstrated tumor growth inhibition across multiple animal tumor models, as well as therapeutic potential in models of autoimmune disease.